ProCE Banner Activity

Myth Busting in Psychopharmacology

Slideset

This presentation on myth busting in psychopharmacology reviews the impact that anticholinergic medications can have on patients prescribed antipsychotic medications and the differences among different medications used to treat chronic insomnia, including the new class of dual orexin receptor antagonists (DORAs).

Released: March 22, 2022

Expiration: March 21, 2023

No longer available for credit.

Share

Faculty

Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Leslie J. Citrome, MD, MPH, has disclosed that he has received consulting fees from AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, MedavanteProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, and Teva and has ownership interest in Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, and Pfizer.